Engineered KRAS G12D–Reactive T Cells Show Promise in Pancreatic Cancer

Article navigation

Research Watch| August 05 2022

Online ISSN: 2159-8290

Print ISSN: 2159-8274

2022

American Association for Cancer Research

Cancer Discov (2022) 12 (8): 1833.

Abstract

T cells with engineered KRAS G12D–specific TCRs mediated regression of metastases in a patient with pancreatic cancer.

2022

American Association for Cancer Research

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.